Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.

Yamasaki M, Kimura R, Mayahara S, Maeda Y, Takahashi M, Nishida T, Oda K, Murakami T.

Mol Clin Oncol. 2019 Jul;11(1):43-49. doi: 10.3892/mco.2019.1849. Epub 2019 Apr 24.

2.

Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.

Tsuda T, Kyomori C, Mizukami T, Taniyama T, Izawa N, Horie Y, Hirakawa M, Ogura T, Nakajima TE, Tsugawa K, Boku N.

Mol Clin Oncol. 2016 Apr;4(4):603-606. Epub 2016 Feb 5.

4.

Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients.

Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K, Sahashi T, Kuroda J, Ogura H, Uegaki S, Yoshida T, Mori Y, Sawada H, Watanabe S, Sugiura H, Endo Y, Yoshimoto N, Toyama T, Iida S, Yamada K, Kimura K, Wakita A.

J Cancer. 2014 Apr 24;5(5):390-7. doi: 10.7150/jca.7706. eCollection 2014.

5.

Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.

Fujii T, Nishimura N, Urayama KY, Kanai H, Ishimaru H, Kawano J, Takahashi O, Yamauchi H, Yamauchi T.

Anticancer Res. 2015 Jan;35(1):379-83.

PMID:
25550575
6.

Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.

Boccia R, Geller RB, Clendeninn N, Ottoboni T.

Future Oncol. 2019 Jan;15(3):297-303. doi: 10.2217/fon-2018-0662. Epub 2018 Oct 10.

7.

[Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].

Yang D, Tong F, Cao Y, Liu P, Zhou B, Liu H, Qiao X, Zhang J.

Zhonghua Zhong Liu Za Zhi. 2002 May;24(3):303-5. Chinese.

PMID:
12515634
8.

Prevention of venous pain and phlebitis caused by epirubicin hydrochloride.

Sugimoto M, Matsui M, Harada M, Yamauchi Y, Moriyama N, Andou K, Yamamoto M, Yamaoka H, Ono C, Ishikawa M, Kamo N, Ikeda T, Yamaoka K.

Gan To Kagaku Ryoho. 2009 Jun;36(6):969-74.

PMID:
19542717
9.

Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men.

Azuma J, Fukase H.

Clin Pharmacol Drug Dev. 2013 Oct;2(4):394-9. doi: 10.1002/cpdd.58. Epub 2013 Aug 26.

PMID:
27121944
10.
11.

Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.

Tan QW, Luo T, Zheng H, Tian TL, He P, Chen J, Zeng HL, Lv Q.

Chin J Cancer. 2017 Mar 7;36(1):27. doi: 10.1186/s40880-017-0196-5.

12.

Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.

Chau E, Lundberg J, Phillips G, Berger M, Wesolowski R.

J Oncol Pharm Pract. 2019 Jul;25(5):1053-1057. doi: 10.1177/1078155218769347. Epub 2018 Apr 13.

PMID:
29651918
13.

[Promising new injection method to prevent angialgia/phlebitis from epirubicin hydrochloride therapy for breast cancer].

Ono C, Yamagami M, Kamatani R, Yamamoto M, Mukouyama T, Sugimoto M, Suzuki T, Kamo N, Seki N, Eguchi K, Ikeda T.

Gan To Kagaku Ryoho. 2012 May;39(5):777-81. Japanese.

PMID:
22584330
14.

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.

Sandström M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO.

Cancer Chemother Pharmacol. 2006 Aug;58(2):143-56. Epub 2006 Feb 8.

PMID:
16465545
15.

Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations.

Tariq M, Alam MA, Singh AT, Panda AK, Talegaonkar S.

Drug Deliv. 2016 Oct;23(8):2990-2997. Epub 2016 Jan 22.

PMID:
26800371
16.

An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.

Hegerova LT, Leal AD, Grendahl DC, Seisler DK, Sorgatz KM, Anderson KJ, Hilger CR, Loprinzi CL.

Support Care Cancer. 2015 Jan;23(1):55-9. doi: 10.1007/s00520-014-2326-9. Epub 2014 Jun 26.

17.

Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.

Gu X, Jia S, Wei W, Zhang WH.

Tumour Biol. 2015 Jul;36(7):5529-35. doi: 10.1007/s13277-015-3221-9. Epub 2015 Feb 15.

PMID:
25682286
18.

Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.

Celio L, Ricchini F, De Braud F.

Patient Prefer Adherence. 2013 May 7;7:391-400. doi: 10.2147/PPA.S31288. Print 2013.

19.

[Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].

Zang MF, Zhang YM, Zhi YH, Zhai Z, Zhang M, Gu F, Zhi XC.

Zhonghua Yi Xue Za Zhi. 2011 May 31;91(20):1388-92. Chinese.

PMID:
21756809
20.

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.

Leal AD, Kadakia KC, Looker S, Hilger C, Sorgatz K, Anderson K, Jacobson A, Grendahl D, Seisler D, Hobday T, Loprinzi CL.

Support Care Cancer. 2014 May;22(5):1313-7. doi: 10.1007/s00520-013-2089-8. Epub 2014 Jan 9.

Supplemental Content

Support Center